Related Experiment Video
Updated: Feb 19, 2026
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
4SC-202 as a Potential Treatment for the Pediatric Brain Tumor Medulloblastoma
Shanta M Messerli1, Mariah M Hoffman2, Etienne Z Gnimpieba3
1Sanford Children's Health Research Center, Department of Pediatrics, Cancer Biology and Immunotherapies, Sanford Research, Sanford School of Medicine, University of South Dakota, Vermillion, SD 57069, USA. Shanta.Messerli@sanfordhealth.org.
Abstract:
This project involves an examination of the effect of the small molecule inhibitor 4SC-202 on the growth of the pediatric brain cancer medulloblastoma. The small molecule inhibitor 4SC-202 significantly inhibits the viability of the pediatric desmoplastic cerebellar human medulloblastoma cell line DAOY, with an IC50 = 58.1 nM, but does not affect the viability of noncancerous neural stem cells (NSC). 4SC-202 exposure inhibits hedgehog expression in the DAOY cell line. Furthermore, microarray analysis of human medulloblastoma patient tumors indicate significant upregulation of key targets in the Hedgehog signaling pathway and Protein Tyrosine Kinase (PTK7).
